AP NEWS

DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool (Online Access) - ResearchAndMarkets.com

November 7, 2018

DUBLIN--(BUSINESS WIRE)--Nov 7, 2018--The “DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool” has been added to ResearchAndMarkets.com’s offering.

DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool is the most up to date and comprehensive commercial pipeline review and competitive assessment available on this hot and fast moving area in oncology. This unique product is truly the only one of its kind and is designed to give you a competitive edge in your DDR drug intelligence.

This tool covers more than 390 companies plus partners who are today developing 820 DDR drugs where of 491 are in active development in cancer across 220 different targets. Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing with your own proprietary information.

With a simple point and click interface you can navigate the environment of current development, drill down into specific areas such as ongoing combination trials, biomarker analysis, selected scientific abstracts etc. and generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts). Any analysis generated by you is packed with presentation-ready graphs and tables to use in your reports and presentations.

The tool is continuously updated according to twelve of the world’s most influential meetings in oncology (AACR, ASCO, ASGCT, ASH, CIMT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International, Europe and Asia). If you are not able to attend any of the conference(s) in person, this Analytical Tool ensures that you are not missing out on the important take home messages you need to know about.

The tool delivers comprehensive combination therapy analysis, allowing you to analyze combination therapies from multiple perspectives; from a single drug to virtually any cross section of oncology drugs of interest.

The tool also provide an outstanding oncology clinical biomarker surveillance & analysis, highlighting clinical phenotyping and patient stratification in trials. This analysis is based on our monitoring of the presence and usage of more than 1,000 biomarkers across tens of thousands of cancer clinical trials.

For more information about this tool, visit https://www.researchandmarkets.com/research/wp2rh8/dna_damage?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181107005452/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Genomics,Oncology Drugs,Molecular Diagnostics

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES ONCOLOGY

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 11/07/2018 06:50 AM/DISC: 11/07/2018 06:50 AM

http://www.businesswire.com/news/home/20181107005452/en

AP RADIO
Update hourly